brofaromine brofaromine brofaromine (proposed brand name consonar) is a reversible inhibitor of monoamine oxidase a (rima) discovered by ciba-geigy. the compound was primarily researched in the treatment of depression and anxiety but its development was dropped before it was brought to market. brofaromineclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status in general: ℞ (prescription only) pharmacokinetic dataprotein binding98%elimination half-life9-14 hoursidentifiers iupac name 4-(7-bromo-5-methoxybenzofuran-2-yl)piperidine cas number63638-91-5 ypubchem cid44571chemspider40549 yunii6wv4b8q07hkeggd02560 ychemblchembl160347 ycomptox dashboard (epa)dtxsid10213008 chemical and physical dataformulac14h16brno2molar mass310.191 g·mol−13d model (jsmol)interactive image smiles brc3cc(oc)cc1c3oc(c1)c2ccncc2 inchi inchi=1s/c14h16brno2/c1-17-11-6-10-7-13(9-2-4-16-5-3-9)18-14(10)12(15)8-11/h6-9,16h,2-5h2,1h3 ykey:wzxhswvdayofpe-uhfffaoysa-n y (verify) brofaromine also acts as a serotonin reuptake inhibitor, and its dual pharmacologic effects offered promise in the treatment of a wide spectrum of depressed patients while producing less severe anticholinergic side effects in comparison with older standard drugs like the tricyclic antidepressants. pharmacology brofaromine is a reversible inhibitor of monoamine oxidase a (rima, a type of monoamine oxidase inhibitor (maoi)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. unlike standard maois, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.